1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–1217
2. Brainard DM, Perty A, van Dyck K, Nachbar RB, de Lepeleire I, Caro L, Stone JA et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52:706A–707A
3. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourliere M et al (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131:1040–1048
4. Brown NA, Vig P, Ruby E, Muchnik A, Pottorf E, Knox SJ, Febbraro S et al (2010) Safety and pharmacokinetics of PPI-461, a potent new hepatitis C virus NS5A inhibitor with pan-genotype activity. Hepatology 52:S464
5. Chayama K, Takahashi S, Kawakami Y, Ikeda K, Suzuki F, Toyota J, Karino Y et al (2011) Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 54:1428A